Submitted New Drug Application for vepdegestrant for the treatment of ESR1m, ER+/HER2- advanced or metastatic breast cancer – ...

Q2 2025 Earnings Call Transcript August 6, 2025 Arvinas, Inc. beats earnings expectations. Reported EPS is $-0.83836, ...

The smaller market now envisioned for vepdegestrant has changed both companies’ stance on their original deal, leading to negotiations that could either lead to a new alliance or Arvinas to seek a new ...

Discover key insights from Arvinas, Inc.'s Q2 2025 earnings call, including CEO transition, clinical milestones, Pfizer partnership updates, and ...

Shares of Arvinas Inc. (ARVN) fell 4% on Thursday as Wall Street sounded contradicting opinions on the future of its ...

On January 16, 2025, Avacta reported encouraging results from its Phase I trial of AVA6000. In patients with salivary gland ...

Ultragenyx Pharmaceutical RARE reported second-quarter 2025 loss of $1.17 per share, narrower than the Zacks Consensus ...

The neuroendocrine prostate cancer treatment space will experience significant changes during the forecast period of 2025–2034, owing to the launch o ...

Detailed price information for GE Healthcare Technologies Inc (GEHC-Q) from The Globe and Mail including charting and trades.

Sarepta reported a quarter-on-quarter dip in sales for its Duchenne gene therapy. Elsewhere, Jazz won FDA approval of a brain cancer drug and Novo decided to advance a Prothena medicine into Phase 3.